Navigation Links
Texas Children's Hospital Selects Hyland Software's OnBase to Complete Electronic Medical Records Initiative
Date:10/4/2007

le electronic repository, the delivery of care patients receive will be more efficient."

About Hyland Software Healthcare Solutions

Hyland Software Inc. is the developer of OnBase, a rapidly deployable suite of enterprise content management (ECM) software applications. OnBase is a modular suite of ECM applications that includes document imaging, workflow, electronic document management, COLD/ERM and records management. OnBase Healthcare Solutions enable organizations to run more efficiently by managing content and streamlining workflows across the enterprise with point solutions for revenue cycle management, medical records and back office operations. For more information about OnBase, please contact an Authorized OnBase Solution Provider or visit http://www.onbase.com.

Contact:

Lindsay McCune

Public Relations Manager

Hyland Software Inc.

(440) 788-6029

lindsay.mccune@onbase.com

"Oracle, JD Edwards, PeopleSoft, and Siebel are registered trademarks of Oracle Corporation and/or its affiliates."


'/>"/>
SOURCE Hyland Software
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. A Baffling New Drug Plan In Texas Town
2. Texas Lends a Hand for “Own Your Future” Health Campain
3. Smoking in Public Places Banned, In Texas
4. North Texas Surgeons Lead Robotically Assisted Laparoscopic Surgeries.
5. Texas Requires Cancer Vaccine for Girls
6. Texas Youth Commission Reeling Under Multiple Charges
7. Students of Texas A&M University Going Trans-Fat Free
8. Texas Lawmakers Give The Boot To Cervical Cancer Vaccine
9. Texas Passes Bill To Halt Order Mandating HPV Vaccine for School Girls
10. Mother Hangs Herself and Three Children in Texas
11. Seven Children Ordered Removed from Squalid Home in Texas
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 1National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 1Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 2Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 4Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 5Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 6Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 7Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 8Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 1Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 2